C4 Therapeutics (CCCC) Cash Flow: Operating & Free Cash Flow

C4 Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for C4 Therapeutics, Inc. (CCCC) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Operating Activities
Net Income	-104.99	-105.32	-132.49	-128.18	-83.89	-66.34	-34.10	-15.71
Depreciation & Amortization	1.96	1.82	1.88	1.68	1.49	1.62	1.60	1.27
Deferred Income Tax	0.00	0.00	0.00	0.00	1.88	5.58	0.35	0.07
Stock Based Compensation	19.10	29.66	27.24	30.02	21.51	3.43	1.64	0.58
Change in Working Capital	-29.28	7.65	-6.94	-16.78	-30.09	-13.18	84.98	-5.56
Change in Accounts Receivable	0.70	8.70	-10.33	4.24	-1.23	0.14	81.82	-84.94
Change in Inventory	0.00	0.00	0.00	0.00	-2.63	-1.58	2.17	-2.22
Change in Accounts Payable	-0.47	-0.12	0.27	-3.33	-1.18	0.47	4.23	0.58
Change in Other Working Capital	-29.52	-9.55	-0.66	-0.12	0.72	-12.20	-3.24	81.03
Other Operating Activities	14.52	1.03	6.86	7.32	0.72	1.63	1.14	2.37
Net Cash from Operating Activities	-98.69	-65.16	-106.84	-105.94	-86.97	-67.25	55.61	-16.98
Investing Activities
Capital Expenditures	-0.61	-0.18	-1.71	-5.50	-1.28	-0.65	-1.35	-2.69
Acquisitions	0.00	0.00	0.00	-63.92	188.06	189.86	0.06	0.00
Purchases of Investments	-227.07	-284.32	160.06	-219.53	-537.74	-293.86	-79.00	-4.99
Sales/Maturities of Investments	219.08	233.23	289.96	283.45	349.68	104.00	78.67	44.60
Other Investing Activities	0.00	0.00	0.00	63.92	-188.06	-189.86	0.00	39.61
Net Cash from Investing Activities	-8.60	-51.27	158.35	58.42	-189.34	-190.51	-1.62	36.92
Financing Activities
Debt Repayment	0.00	0.00	-12.50	0.00	0.00	11.97	0.00	0.00
Common Stock Issued	126.32	45.15	57.73	0.78	169.47	340.60	0.00	0.05
Common Stock Repurchased	-0.19	-0.19	-0.11	0.00	0.00	-0.19	-0.03	-0.06
Other Financing Activities	0.27	0.38	0.37	0.37	-0.40	-3.45	0.27	1.91
Net Cash from Financing Activities	126.40	45.34	45.49	1.15	171.40	348.93	0.24	1.96
Summary
Net Change in Cash	19.10	-71.09	97.00	-46.37	-104.90	91.18	54.24	21.90
Cash at Beginning of Period	58.94	130.03	33.03	79.40	184.30	93.13	38.89	16.99
Cash at End of Period	78.05	58.94	130.03	33.03	79.40	184.30	93.13	38.89
Free Cash Flow	-99.30	-65.34	-108.55	-111.44	-88.24	-67.90	54.27	-19.67
Supplemental Disclosures
Interest Paid	-	-	0.99	1.62	1.31	0.82	-	-
Income Taxes Paid	-	-	1.00	-	-	0.14	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About C4 Therapeutics Cash Flow

What is C4 Therapeutics's free cash flow?

C4 Therapeutics had negative free cash flow of $99.30M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$98.69M minus $607.00K of capital expenditures.

How much does C4 Therapeutics spend on capital expenditures?

C4 Therapeutics spent $607.00K on capital expenditures in fiscal 2025, compared with $180.00K a year earlier.

Does C4 Therapeutics pay dividends or buy back shares?

Yes. In fiscal 2025 C4 Therapeutics returned $193.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition